Business Context and Reporting Period
Company: Spero Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 28, 2026
Reporting Period: Specific event date of August 28, 2026.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The document focuses on capital raising mechanisms and liquidity management.
- Proposed Offering Capacity: Up to $100,000,000 in common stock via a new Open Market Sale Agreement with Jefferies LLC.
- Underlying Shelf Capacity: Part of a universal shelf Registration Statement (Form S-3) for up to $300,000,000 in various securities.
- Agent Compensation: Up to 3.0% of aggregate gross proceeds for Jefferies LLC.
- Previous ATM Capacity: $75,000,000 under a terminated agreement with Cantor Fitzgerald & Co.
- Debt and Liquidity: The filing text does not provide specific values for current debt levels, cash balances, or liquidity ratios.
Material Changes Versus Prior Period
The primary material change is the replacement of the company's at-the-market (ATM) sales facility.
- Termination of Prior Agreement: The Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., entered into on March 11, 2021, was terminated effective August 28, 2026.
- Utilization of Prior Agreement: The Company sold no shares under the Cantor agreement during the fiscal years ended December 31, 2025, and 2024.
- Termination Costs: No termination penalties were incurred.
- New Agreement: Entry into a new Open Market Sale Agreement with Jefferies LLC to facilitate future sales of common stock.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company intends to utilize the new Sale Agreement with Jefferies to sell shares "at-the-market" once the underlying Registration Statement is declared effective. The Company retains discretion over the timing and amount of sales.
Risks and Contingencies:
- Regulatory Status: The Registration Statement is not yet effective; no sales may occur until the SEC declares it effective.
- Market Conditions: Jefferies is not required to sell a specific amount of securities and will act using commercially reasonable efforts.
- Dilution: Future sales of common stock under the new agreement will result in dilution to existing shareholders.
- Legal Limitations: The 8-K filing does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Important Facts for Investor Verification
- Verify the effectiveness status of the Form S-3 Registration Statement filed on August 28, 2026, as sales cannot commence until effective.
- Confirm the current cash position and burn rate of Spero Therapeutics to assess the immediate necessity of the $100,000,000 ATM facility.
- Monitor future 8-K filings for actual sales volumes and proceeds generated under the new Jefferies agreement.
- Note that the previous $75,000,000 ATM facility with Cantor was never utilized in the last two fiscal years.